Floatz Rating
C39/100
Confidence
Indicative
Sponsor
AC Immune SA
Modality
UNKNOWN
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple System Atrophy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| [18F]ACI-15916 (this asset) | AC Immune SA | Early P1 | C · 39 |
| Droxidopa | Loma Linda University | P3 | BB |
| Zoledronate | California Pacific Medical Center Research Institute | P4 | BB |
| Ath-434 | Alterity Therapeutics | P2 | B |
| Ioflupane | GE Healthcare | P3 | B |
| Riluzole | King's College London | P3 | B |
| Fipamezole | Juvantia Pharma Ltd | P2 | CCC |
| Exidavnemab | BioArctic AB | P2 | CCC |
| Carbidopa | Daniel Claassen | P1/2 | CCC |
+31 more in the Multiple System Atrophy cohort
Other indications for [18F]ACI-15916
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lewy Body Dementia | — | Early P1 | C · 39 |
| Parkinson Disease | — | Early P1 | C · 38 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. [18F]ACI-15916 in Multiple System Atrophy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/18faci-15916-multiple-system-atrophy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →